Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole - Full Text View

Purpose

This randomized pilot trial studies omega-3 fatty acid in preventing joint symptoms in patients with stage I-III breast cancer receiving anastrozole, exemestane, or letrozole. Omega-3 fatty acid supplement may lessen or prevent joint stiffness or pain in patients receiving hormone therapy for breast cancer.

Condition	Intervention
Recurrent Breast Cancer Stage IA Breast Cancer Stage IB Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer	Dietary Supplement: omega-3 fatty acid supplement Other: Placebo Other: Clinical assessments Other: Assessment of therapy complications Procedure: Magnetic Resonance Imaging Procedure: Correlative/special studies


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Investigator, Outcomes Assessor Primary Purpose: Supportive Care
Official Title:	Prevention of Aromatase Inhibitor-Induced Joint Symptoms With Omega 3 Fatty Acid Supplementation: a Randomized Placebo Controlled Pilot Study

Resource links provided by NLM:

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer

Drug Information available for: Omega-3 Fatty Acids

U.S. FDA Resources

Further study details as provided by Maryam Lustberg, Ohio State University Comprehensive Cancer Center:

Primary Outcome Measures:

Pain score change after 6 months (6 months -baseline) based on the FACT-B/ES instrument [ Time Frame: baseline, 6 months ]
Pain scores based on FACT-B/ES, HAS and BPI will be plotted over time for each arm. Agreement between HAS, BPI-short and FACT-B/ES evaluated using Altman and Bland plot after proper data transformation. Also, Linear Mixed model used to explore if the pain scores are different at 3 and 6 months. Logistic regression models used to compare the occurrence of moderate to severe joint symptoms during the 6 month period between the two treatment groups, with potential covariates including age, body mass index, baseline pain scores (0 month), prior chemotherapy and other variables.

Secondary Outcome Measures:

Pain score change after 6 months (6 months -baseline) based on the HAS and BPI instruments [ Time Frame: baseline, 6 months ]
Agreement between HAS, BPI-short and FACT-B/ES evaluated using Altman and Bland plot after proper data transformation. Also, Linear Mixed model used to explore if the pain scores are different at 3 and 6 months. Logistic regression models used to compare the occurrence of moderate to severe joint symptoms during the 6 month period between the two treatment groups, with potential covariates including age, body mass index, baseline pain scores (0 month), prior chemotherapy and other variables.
Compliance rates with oral supplements (omega-3 fatty acid and placebo) [ Time Frame: baseline, 6 months ]
Feasibility of using the instruments HAS, BPI-short, FACT-B/ES for the assessment of joint symptoms [ Time Frame: baseline, 6 months ]
Effectiveness of blinding [ Time Frame: baseline, 6 months ]
Summarized using a Chi-square test.
Correlation of guess with pain scores [ Time Frame: baseline, 6 months ]
Checked using logistic models to see if treatment guesses are explained by the patient's awareness of clinical benefit.
Relationship between serum and RBC omega-3 fatty acid levels, inflammatory blood markers and MRI changes and the joint symptoms [ Time Frame: baseline, 6 months ]
Scatter plots and correlation coefficients (either Pearson or Spearman) will be used to summarize their pair wise relation. The differences between the treatment and placebo in terms of these measures will also be reported using numerical summaries and graphic plots.


Estimated Enrollment:	40
Study Start Date:	October 2011
Primary Completion Date:	January 2014 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Arm I (omega-3 fatty acid supplement) Omega 3 Polyunsaturated Fatty Acids(n-3 PUFA)	Dietary Supplement: omega-3 fatty acid supplement 6 capsules per day (4.3 g)x 6 months Other Names: fish oil omega fatty acid O3FA MNSG-194® n-3 PUFA supplementation Other: Clinical assessments All three instruments will be administered at baseline, at 3 months, 6 months and at additional time intervals when there is a significant change in therapy (discontinuation/switch, pain medication administration) during routine medical oncology visits. Other Names: Brief Pain Inventory BPI Stanford's Health Assessment-Disability Index HAS FACT-B and endocrine subscale FACT-ES Other: Assessment of therapy complications Severity/grade of reaction according to the NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Other Names: adverse events toxicities Expected Toxicities Potential Toxicities Procedure: Magnetic Resonance Imaging Optional bilateral hand and wrist MRI imaging will be obtained at baseline and at 6 months to eligible patients who have no contraindications to MRI imaging. Other Names: MRI NMR imaging NMRI nuclear magnetic resonance imaging Procedure: Correlative/special studies Plasma, RBC, and serum samples from the baseline blood draw will also be stored at -70C for fatty acid and biomarker analyses and repeated at 3 month and 6 month intervals. Samples will be analyzed in batches every 6 months. Other Name: laboratory studies
Placebo Comparator: Arm II (placebo) Typical American Diet oils (TAD)	Other: Placebo 6 capsules per day (4.3 g)x 6 months. Supplement should be taken with food once per day. No specific food requirements are needed. Other Names: PLCB Typical American Diet oils TAD Other: Clinical assessments All three instruments will be administered at baseline, at 3 months, 6 months and at additional time intervals when there is a significant change in therapy (discontinuation/switch, pain medication administration) during routine medical oncology visits. Other Names: Brief Pain Inventory BPI Stanford's Health Assessment-Disability Index HAS FACT-B and endocrine subscale FACT-ES Other: Assessment of therapy complications Severity/grade of reaction according to the NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Other Names: adverse events toxicities Expected Toxicities Potential Toxicities Procedure: Magnetic Resonance Imaging Optional bilateral hand and wrist MRI imaging will be obtained at baseline and at 6 months to eligible patients who have no contraindications to MRI imaging. Other Names: MRI NMR imaging NMRI nuclear magnetic resonance imaging Procedure: Correlative/special studies Plasma, RBC, and serum samples from the baseline blood draw will also be stored at -70C for fatty acid and biomarker analyses and repeated at 3 month and 6 month intervals. Samples will be analyzed in batches every 6 months. Other Name: laboratory studies
Experimental: Clinical Assessments Brief Pain Inventory (BPI), Stanford's Health Assessment-Disability Index (HAS), FACT-B and endocrine subscale (FACT-ES)	Dietary Supplement: omega-3 fatty acid supplement 6 capsules per day (4.3 g)x 6 months Other Names: fish oil omega fatty acid O3FA MNSG-194® n-3 PUFA supplementation Other: Placebo 6 capsules per day (4.3 g)x 6 months. Supplement should be taken with food once per day. No specific food requirements are needed. Other Names: PLCB Typical American Diet oils TAD
Experimental: Assessment of therapy complications Adverse events will be monitored by self-reporting of signs and symptoms. Patients will maintain a daily diary of time of supplement intake and any possible ill effects, with instructions to contact the PI or Research Nurse to discuss and manage any possible side effects.	Dietary Supplement: omega-3 fatty acid supplement 6 capsules per day (4.3 g)x 6 months Other Names: fish oil omega fatty acid O3FA MNSG-194® n-3 PUFA supplementation Other: Placebo 6 capsules per day (4.3 g)x 6 months. Supplement should be taken with food once per day. No specific food requirements are needed. Other Names: PLCB Typical American Diet oils TAD
Experimental: Magnetic Resonance Imaging Optional bilateral hand and wrist MRI imaging will be obtained	Dietary Supplement: omega-3 fatty acid supplement 6 capsules per day (4.3 g)x 6 months Other Names: fish oil omega fatty acid O3FA MNSG-194® n-3 PUFA supplementation Other: Placebo 6 capsules per day (4.3 g)x 6 months. Supplement should be taken with food once per day. No specific food requirements are needed. Other Names: PLCB Typical American Diet oils TAD
Experimental: Correlative/special studies Enrolled participants will have peripheral blood samples drawn for plasma and RBC n-3 PUFA levels within 4 weeks of starting AI therapy.	Dietary Supplement: omega-3 fatty acid supplement 6 capsules per day (4.3 g)x 6 months Other Names: fish oil omega fatty acid O3FA MNSG-194® n-3 PUFA supplementation Other: Placebo 6 capsules per day (4.3 g)x 6 months. Supplement should be taken with food once per day. No specific food requirements are needed. Other Names: PLCB Typical American Diet oils TAD

Detailed Description:

OBJECTIVES:

I. To assess the feasibility of evaluating joint symptoms in postmenopausal women with breast cancer randomized to n-3 PUFA (omega-3 fatty acid) vs. placebo supplementation using the Functional Assessment of Cancer Therapy-Breast (FACT-B) and endocrine subscale (FACT-ES), Brief Pain Inventory (BPI) and Stanford's Health Assessment -Disability Index (HAS) during the first 6 months of adjuvant aromatase inhibitor (AI) therapy.

II. To preliminarily evaluate the efficacy of n-3 PUFA vs. placebo supplementation on AI induced joint symptoms.

III. To explore blood and imaging based biomarkers (plasma and red blood cell [RBC] levels of n-3 PUFAs, inflammatory cytokines and receptors, and intra-articular tenosynovial inflammation by musculoskeletal magnetic resonance imaging [MRI] imaging) of AI-induced joint symptoms in women on AI therapy randomized to n-3 PUFAs vs. placebo supplementation.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive omega-3 fatty acid orally (PO) once daily (QD) for 6 months in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Women diagnosed with breast cancer stages I-III initiating first adjuvant AI therapy with any of the Food and Drug Administration- (FDA) approved AIs (anastrozole, exemestane, letrozole)
Concurrent gonadotropin-releasing hormone (GnRH) agonist therapy is allowed
Concurrent breast related radiation therapy is allowed
Prior tamoxifen use is allowed
Prior chemotherapy is allowed
History of osteoarthritis and/or fibromyalgia is allowed
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

Metastatic malignancy of any kind
Rheumatoid arthritis and other types of autoimmune and inflammatory joint disease, with the exception of osteoarthritis and fibromyalgia
AI use > 2 weeks prior to study enrollment
Known bleeding disorders
History of diabetes mellitus, heart disease or TIA/stroke
Current use of warfarin or other anticoagulants
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia,or psychiatric illness/social situation that would limit compliance with study requirements
Daily use of n-3 PUFA concentrates or capsules or regular or any other supplements that might interact with n-3 PUFA supplements within six months of study initiation; sporadic use of n-3 PUFA supplement may be eligible if there has been a 3-month washout period prior to randomization
Pregnant or nursing women
Known sensitivity or allergy to fish or fish oil
Concurrent use of daily full dose aspirin (≥ 325 mg/day), nonsteroidal anti-inflammatory drugs (NSAIDs) or NSAID-containing products or steroids; one month washout period is required prior to randomization
Unable to give informed consent
In patients consenting for optional MRIs, any contraindication to MRI examination including but not limited to ferromagnetic metal in the body, pacemaker, or severe claustrophobia

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01478477

Locations


United States, Ohio
Ohio State University Medical Center
Columbus, Ohio, United States, 43210

Sponsors and Collaborators

Ohio State University Comprehensive Cancer Center

Cancer and Leukemia Group B

Investigators


Principal Investigator:	Maryam Lustberg, MD	Ohio State University

More Information

Additional Information:

Jamesline

This link exits the ClinicalTrials.gov site


Responsible Party:	Maryam Lustberg, Principal Investigator, Ohio State University Comprehensive Cancer Center
ClinicalTrials.gov Identifier:	NCT01478477 History of Changes
Other Study ID Numbers:	OSU-11022 NCI-2011-03262 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
Study First Received:	November 14, 2011
Last Updated:	January 28, 2017

Keywords provided by Maryam Lustberg, Ohio State University Comprehensive Cancer Center:


Breast Cancer

Additional relevant MeSH terms:


Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases

ClinicalTrials.gov processed this record on May 25, 2017